🔴 Humacyte is trading 12.9% down amid a broad market selloff

Humacyte is trading at $0.41, 12.9% down, amid a broad market selloff; broader weakness is context, not a confirmed cause of the decline.

• In a late-morning report on October 30, the Nasdaq was down 2.1%, the S&P 500 1.3%, and the Dow 0.5%.
• No clear company-specific announcement explaining the decline was found for October 30. Humacyte’s most recent listed releases were dated October 23 and October 15; the October 28 patent announcement is prior news, not a confirmed catalyst.